Navigation Links
Exergen Granted New Patent for Temporal Artery Thermometers

WATERTOWN, Mass., March 17, 2011 /PRNewswire/ -- A recently issued patent extends protection of the technology incorporated in Exergen's award winning and best selling medical thermometer brand, the TemporalScanner™ Temporal Artery Thermometers.  Exergen Corporation has recently been granted U.S. Patent No. 7,787,938, entitled, "Temporal Artery Temperature Detector" by the US Patent and Trademark Office, adding to the already extensive Exergen portfolio of valuable intellectual property rights that it has developed for its non-invasive thermometry products.

With 15 US Patents protecting the TemporalScanner professional versions, and 10 US Patents protecting the home model, Exergen continues to vigorously defend its intellectual property rights.  It has brought a number of lawsuits over the years to successfully stop companies from infringing upon Exergen's rights with regard to infrared temperature measuring products. Currently Exergen has brought suit against Kidz-Med, Inc., American Scientific Resources, Inc. and Tecnimed S.R.L for patent infringement in the United States District Court for the District of Massachusetts.

"This new patent confirms and protects important innovations in non-invasive thermometry contained in our Temporal Artery Thermometers," said Dr. Francesco Pompei, Exergen CEO and inventor of the patented technology.  "These innovations are central to the overwhelming success of the temporal artery method, which many competitors would like to use.  As a U.S. manufacturer we rely on strong patent protection to protect our rights, and do our part to help protect the spirit of innovation in a highly competitive world."

Exergen Corporation is recognized worldwide as an innovator and leading manufacturer of patented infrared thermometers, scanners, sensors and controls.  Its products are used in a wide variety of industrial and medical applications for both professionals and consumers.  Its TemporalScanner medical thermometers are responsible for nearly a billion temperatures taken per year in thousands of hospitals and clinics.  Its home model is used in more than 3 million homes and is the #1 selling retail brand. For additional information, visit

SOURCE Exergen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Exergen TemporalScanner Effective in Detecting Fevers in Children Aged 1-4 Years, Study Finds
2. Exergen TemporalScanner Thermometer Best Selling Brand at Retailers
3. Exergen TemporalScanner Sponsors Game Time Temperature for NFL and College Bowl Games
4. Exergen Game Time Temperature Contest Helps Football Fans Tackle Cold and Flu Season
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
9. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
10. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
11. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
Post Your Comments:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):